98581-86-3

Usage

Uses

Used in Polymer Production:
4-(4H-1,2,4-Triazol-4-yl)phenol is used as a chelating agent in the production of polymers to facilitate the binding and removal of metal ions, which can enhance the polymerization process and improve the quality of the final product.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-(4H-1,2,4-Triazol-4-yl)phenol is used as an intermediate in the synthesis of various drugs. Its ability to inhibit certain enzymes and processes in the human body is being researched for potential therapeutic applications.
Used in Agricultural Chemicals:
4-(4H-1,2,4-Triazol-4-yl)phenol is utilized as a chelating agent in the production of agricultural chemicals, where it helps in the efficient delivery of nutrients and metal ions to plants, thereby enhancing crop growth and yield.
Used in Metal Plating:
This chemical is used as a chelating agent in metal plating processes to bind and remove metal ions from solutions, which aids in achieving a uniform and high-quality metal coating on various surfaces.
Used in Water Treatment:
4-(4H-1,2,4-Triazol-4-yl)phenol is employed in water treatment processes to remove metal ions from water, contributing to the purification of water and making it safe for various uses.
It is important to handle 4-(4H-1,2,4-Triazol-4-yl)phenol with care due to potential health and safety risks if not used properly.

InChI:InChI=1/C6H12N2O2/c7-2-4-8-3-1-5-10-6(8)9/h1-5,7H2

Upstream product

• 123-30-8 4-amino-phenol 
• 624-84-0 formic acid hydrazide 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 628-36-4 diformylhydrazine 

Relevant academic research and scientific papers

Synthesis and anti-inflammatory activity evaluation of novel 3-alkyl-6-(4H-1,2,4-triazol-4-yl)-3,4-dihydro-2H-benzo[e][1,3]oxazine derivatives

To discover new compounds with anti-inflammatory activity, a series of novel 3-alkyl-6-(4H-1,2,4-triazol-4-yl)-3,4-dihydro-2H-benzo[e][1,3]oxazine derivatives were synthesized and their structures were confirmed by spectroscopic techniques. In vivo anti-inflammatory activity of the synthesized compounds was determined using the xylene-induced mouse ear edema model. 3-Heptyl-6-(4H-1,2,4-triazol-4-yl)-3,4-dihydro-2H-benzo[e] [1,3]oxazine and 3-p-tolyl-6-(4H-1,2,4-triazol-4-yl)-3,4-dihydro-2H-benzo[e][1,3]oxazine demonstrated higher anti-inflammatory activity (74.04 % and 64.99 %, respectively) at 0.5 h after intraperitoneal administration than the reference drug ibuprofen (62.65 %). Further, the time of peak effect after oral administration was 4 h for both compounds. Our results identify new compounds with anti-inflammatory activity in vivo that may have improved safety/side effect profiles relative to the currently approved nonsteroidal anti-inflammatory drugs.

Synthesis of 1,3,4-oxadiazole derivatives with anticonvulsant activity and their binding to the GABAA receptor

In this study, a series of 1,3,4-oxadiazole derivatives (5a-s, 10a-s, and 16a-d) were designed and synthesized using maximal electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ) models, to test the anticonvulsant activity of the target compounds

Design, synthesis, and anticonvulsant effects evaluation of nonimidazole histamine H3 receptor antagonists/inverse agonists containing triazole moiety

Histamine H3 receptors (H3R) antagonists/inverse agonists are becoming a promising therapeutic approach for epilepsy. In this article, novel nonimidazole H3R antagonists/inverse agonists have been designed and synthesised via hybriding the H3R pharmacophore (aliphatic amine with propyloxy chain) with the 1,2,4-triazole moiety as anticonvulsant drugs. The majority of antagonists/inverse agonists prepared here exerted moderate to robust activities in cAMP-response element (CRE) luciferase screening assay. 1-(3-(4-(3-Phenyl-4H-1,2,4-triazol-4-yl)phenoxy)propyl)piperidine (3l) and 1-(3-(4-(3-(4-chlorophenyl)-4H-1,2,4-triazol-4-yl)phenoxy)propyl)piperidine (3m) displayed the highest H3R antagonistic activities, with IC50 values of 7.81 and 5.92 nM, respectively. Meanwhile, the compounds with higher H3R antagonistic activities exhibited protection for mice in maximal electroshock seizure (MES)-induced convulsant model. Moreover, the protection of 3m against the MES induced seizures was fully abrogated when mice were co-treated with RAMH, a CNS-penetrant H3R agonist, which suggested that the potential therapeutic effect of 3m was through H3R. These results indicate that the attempt to find new anticonvulsant among H3R antagonists/inverse agonists is practicable.

SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

Substituted cyclopropyl compounds of formula (I) are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.